ABA |
Applied behavioral analysis |
IQ |
Intelligence (Quotient) |
ACTH |
Adrenocorticotropic hormone, corticotropin |
LGS |
Lennox–Gastaut syndrome |
AD |
Antidepressant |
LKS |
Landau–Kleffner syndrome |
AD |
|
MAOI |
Monoamino oxidase inhibitor |
ADHD |
Attention deficit/hyperactivity syndrome |
MPEP |
2‑methyl-6- (phenylethynyl)pyridine |
BD |
Bipolar disorder |
MT1 |
Melatonin 1 (receptor) |
ASD |
Autism spectrum disorder |
NDRI |
Norepinephrine-dopamine reuptake inhibitor |
BPD |
Borderline personality disorder |
NMDA |
N‑methyl-D-aspartate |
CBT |
Cognitive behavioral therapy |
OCD |
Obsessive compulsive disorder |
CSWS |
Continuous spike waves during slow-wave sleep |
ODD/CD |
Oppositional defiant disorder/conduct disorder |
DSM‑5 |
Diagnostic and Statistic Manual for Mental Disorders, 5th edition |
PE |
Partial epilepsy |
DRESS |
Drug rash with eosinophilia and systemic symptoms |
PECS |
Picture exchange communication system |
EF |
Executive functions (functioning) |
REM sleep |
Rapid eye movement sleep |
ESES |
Electrical status epilepticus during slow-wave sleep |
RLS |
Restless legs syndrome |
FDA |
Food and Drug Administration |
SGA |
Second generation antipsychotic |
FGA |
First generation antipsychotic |
SSRI |
Selective serotonin reuptake inhibitor |
FXS |
Fragile X syndrome |
SNRI |
Selective serotonin and norepinephrine reuptake inhibitor |
GABA |
Gamma-amino-butyric acid |
SE |
Side effects |
GAD |
Generalized anxiety disorder |
|
Half life |
CBT |
Cognitive behavioral therapy |
TCA |
Tricyclic antidepressant |
ICD |
International Classification of Diseases |
TCM |
Traditional Chinese medicine |
ID |
Intellectual disability |
TEACCH |
Treatment and education of autistic and related communication handicapped children |
IGF‑1 |
Insulin-like growth factor – 1 |
VPS |
Valproic acid |